Results 1 to 10 of about 268,751 (268)

Mantle-Cell Lymphoma

New England Journal of Medicine, 2022
Mantle cell lymphoma is a distinct lymphoma subtype with a widely varying clinical course. Established high-risk biological factors include blastoid cytomorphology, high cell proliferation (Ki-67 > 67%), and p53 mutations (Aukema et al. 2018).
James O, Armitage, Dan L, Longo
semanticscholar   +6 more sources

Mantle cell lymphoma

Haematologica, 2009
This perspective article by Drs. Pileri and Falini examines the diagnosis and bio-pathology of mantle cell lymphoma in the light of the criteria of the WHO Classification and recent reports. See related articles on pages 1555, 1563 and 1595.
Stefano A. Pileri, Brunangelo Falini
doaj   +3 more sources

Smoldering mantle cell lymphoma [PDF]

Journal of Experimental & Clinical Cancer Research, 2017
Background Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a
Haige Ye, Aakash Desai, Dongfeng Zeng, Krystle Nomie, Jorge Romaguera, Makhdum Ahmed, Michael L. Wang   +6 more
doaj   +4 more sources

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

Journal of Hematology & Oncology, 2018
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie, Michael Wang   +5 more
doaj   +2 more sources

Indolent mantle cell lymphoma

Haematologica, 2011
Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin’s lymphomas[1][1] and is characterized by the over-expression of cyclin D1 with cell cycle dysregulation, secondary to the genetic abnormality t(11;14)(q13;q32).[2][2] It often has an aggressive clinical course and ...
Michelle Furtado, Simon Rule
doaj   +3 more sources

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Journal of Clinical Oncology, 2022
PURPOSE Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study
Michael Wang, J. Muñoz, A. Goy, F. Locke, C. Jacobson, B. Hill, J. Timmerman, H. Holmes, S. Jaglowski, I. Flinn, P. Mcsweeney, D. Miklos, J. Pagel, M. Kersten, K. Bouabdallah, R. Khanal, M. Topp, R. Houot, A. Beitinjaneh, W. Peng, X. Fang, R. Shen, R. Siddiqi, I. Kloos, P. Reagan   +24 more
semanticscholar   +1 more source

Mantle cell lymphoma [PDF]

Seminars in Cancer Biology, 2011
Le lymphome a cellules du manteau (LCM) est une pathologie qui ne represente que 5 a 8 % des lymphomes malins non hodgkiniens. Le LCM se caracterise par la presence de la translocation reciproque entre les chromosomes 11 et 14 (11;14)(q13;q32). Celle-la induit une augmentation de l’expression de la cycline D1, aboutissant au dereglement du cycle ...
Pierre Peterlin, Anne Moreau, Catherine Pellat-Deceunynck, Carole Brousseau, Thomas Gastinne, Steven Le Gouill, Christelle Dousset, Martine Amiot, Cyrille Touzeau   +8 more
  +8 more sources

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma ...
Michael L. Wang, W. Jurczak, M. Jerkeman, J. Trotman, P. Zinzani, D. Belada, C. Boccomini, I. Flinn, P. Giri, A. Goy, P. Hamlin, O. Hermine, J. Hernández‐Rivas, X. Hong, S. Kim, D. Lewis, Y. Mishima, M. Özcan, G. Perini, C. Pocock, Yuqin Song, S. Spurgeon, J. Storring, J. Walewski, Jun Zhu, Rui Qin, T. Henninger, S. Deshpande, A. Howes, S. le Gouill, M. Dreyling   +30 more
semanticscholar   +1 more source

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Blood, 2022
Treatment of mantle cell lymphoma (MCL) continues to improve. Song et al present longer term outcomes of a phase 2 study of zanubrutinib therapy for 86 patients with relapsed/refractory MCL.
Yuqin Song, K. Zhou, D. Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, J. Ji, Wei-lai Xu, J. Jin, F. Lv, R. Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Jane E. Huang, W. Novotny, P. Kim, Yiling Yu, Binghao Wu, Jun Zhu   +20 more
semanticscholar   +1 more source

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma

Biomedicines, 2022
CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 expression and evaluating pro-phagocytic effects of CD24 antibody treatment in comparison to ...
J. Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, H. Lourens, G. Huls, T. van Meerten, Ewa Cendrowicz, E. Bremer   +7 more
semanticscholar   +1 more source